Program
cyclobenzaprine
Also written as “TNX-102 SL”, “TNX-102 SL 5.6 mg” and “Treatment A”.
Its studies are mostly in Fibromyalgia · Stress Disorders, Post-Traumatic · Depressive Disorder, Major · Post-Acute COVID-19 Syndrome · Neck Pain, led by 7 companies.
Drug pageCyclobenzaprine: every studyMany companies study it; this page follows only the 32 they lead. All 42 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tonix Pharmaceuticals | 262 open or running | phase 3since Jul 12, 2013 | Dec 7, 2011 | Feb 2028phase 2 · NCT07621237 |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Apr 24, 2012 | Apr 24, 2012 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Oct 28, 2005 | Oct 28, 2005 | none ahead |
| Neurana Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| Novartisits history only | 10 open or running | phase 1since Jun 2, 2009 | Jun 2, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Jun 23, 2016 | Jun 23, 2016 | none ahead |
Also a collaborator on its studies: Altasciences, Premier Research Group and Cognitive Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tonix Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 12 studies since Dec 7, 2011.
- Mar 31, 2017Phase 3 study in Stress Disorders, Post-TraumaticNCT03110575 · 190 enrolled · United States
- Apr 25, 2017Phase 1 study in Healthy AdultsNCT03168022 · 43 enrolled · Canada
- Feb 6, 2018Phase 1 study in Healthy SubjectsNCT03443960 · 60 enrolled · Canada
- Apr 12, 2018Phase 3 study in Stress Disorders, Post-TraumaticNCT03508700 · 93 enrolled · United States
- Feb 12, 2019Phase 3 study in Stress Disorders, Post-TraumaticNCT03841773 · 192 enrolled · United States
- Nov 13, 2019Phase 1 study in Healthy SubjectsNCT04164719 · 16 enrolled · Canada
- Nov 20, 2019Phase 3 study in FibromyalgiaNCT04172831 · 503 enrolled · United States
- Aug 7, 2020Phase 3 study in FibromyalgiaNCT04508621 · 514 enrolled · United States
- Mar 1, 2022Phase 3 study in FibromyalgiaNCT05273749 · 457 enrolled · United States
- May 9, 2022Phase 2 study in Stress Disorders, Post-TraumaticNCT05372887 · Kenya
- Jul 21, 2022Phase 2 study in InfectionsNCT05472090 · 63 enrolled · United States
- Jan 26, 2026Phase 1 study in PharmakokineticNCT07413367 · 50 enrolled · Canada
- Mar 6, 2026Phase 1 study in Healthy Subjects (HS)NCT07464535 · 20 enrolled · United States
- May 27, 2026Phase 2 study in Depressive Disorder, MajorNCT07621237 · 360 planned · United States
Ahead
- Feb 2028Primary completion: phase 2 study in Depressive Disorder, MajorNCT07621237
TargetBeta
“Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| Trazodonerule | Angelini Pharma | phase 3 | 14 |
Studies
All 26 Tonix Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07621237Depressive Disorder, Major · United States | 2 | Recruiting | Feb 2028 | 360 |
| NCT07464535Healthy Subjects (HS) · United States | 1 | Completed | Apr 30, 2022 | 20 |
| NCT07413367Pharmakokinetic · Canada | 1 | Active, not recruiting | Feb 10, 2026 | 50 |
| NCT05472090Infections · United States | 2 | Completed | Jul 12, 2023 | 63 |
| NCT05372887Stress Disorders, Post-Traumatic · Kenya | 2 | Withdrawn | Nov 8, 2022 | 0 |
| NCT05273749Fibromyalgia · United States | 3 | Completed | Nov 14, 2023 | 457 |
| NCT04508621Fibromyalgia · United States | 3 | Completed | Nov 1, 2021 | 514 |
| NCT04172831Fibromyalgia · United States | 3 | Completed | Oct 29, 2020 | 503 |
| NCT04164719Healthy Subjects · Canada | 1 | Completed | Dec 24, 2019 | 16 |
| NCT03841773Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Apr 24, 2020 | 192 |
| NCT03508700Stress Disorders, Post-Traumatic · United States | 3 | Completed | Sep 30, 2019 | 93 |
| NCT03443960Healthy Subjects · Canada | 1 | Completed | Apr 9, 2018 | 60 |
| NCT03168022Healthy Adults · Canada | 1 | Completed | Jan 26, 2016 | 43 |
| NCT03110575Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Jul 27, 2018 | 190 |
| NCT03062540Stress Disorders, Post-Traumatic · United States | 3 | Terminated | Jul 27, 2018 | 358 |
| NCT02829814Fibromyalgia · United States | 3 | Terminated | Sep 13, 2016 | 51 |
| NCT02589275Fibromyalgia · United States | 3 | Completed | Sep 28, 2016 | 375 |
| NCT02436096Fibromyalgia · United States | 3 | Completed | Sep 2016 | 519 |
| NCT02421679Stress Disorders, Post-Traumatic · United States | 2 | Completed | May 26, 2016 | 159 |
| NCT02277704Stress Disorders, Post-Traumatic · United States | 2 | Completed | May 2016 | 245 |
| NCT02015234Fibromyalgia · United States | 3 | Completed | Aug 2015 | 158 |
| NCT01903265Fibromyalgia · United States | 3 | Completed | Jul 2014 | 205 |
| NCT01889173Healthy Adults · Canada | 1 | Completed | Dec 2013 | 24 |
| NCT01689259Healthy Adults · Canada | 1 | Completed | Dec 2013 | 24 |
| NCT01634412Healthy Adults · Canada | 1 | Completed | Sep 2013 | 24 |
| NCT01490788Healthy · Canada | 1 | Completed | Dec 30, 2011 | 30 |
How it is read
Names in the registry
- “TNX-102 SL”, 13 entries
- “TNX-102 SL 5.6 mg”, 2 entries
- “Treatment A”, 2 entries
- “Treatment B”, 2 entries
- “TNX-102 SL Tablet”, 1 entry
Codes read as this program: TNX102.
Conditions, from the studies’ own filings
- Fibromyalgia, 8 studies
- Stress Disorders, Post-Traumatic, 7 studies
- Depressive Disorder, Major, 1 study
- Post-Acute COVID-19 Syndrome, 1 study
- Neck Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.